| Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind … V Popova, EJ Daly, M Trivedi, K Cooper, R Lane, P Lim, C Mazzucco, ... American Journal of Psychiatry 176 (6), 428-438, 2019 | 513 | 2019 |
| Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double … CM Canuso, JB Singh, M Fedgchin, L Alphs, R Lane, P Lim, C Pinter, ... American journal of psychiatry 175 (7), 620-630, 2018 | 459 | 2018 |
| Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial EJ Daly, MH Trivedi, A Janik, H Li, Y Zhang, X Li, R Lane, P Lim, AR Duca, ... JAMA psychiatry 76 (9), 893-903, 2019 | 434 | 2019 |
| Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind … M Fedgchin, M Trivedi, EJ Daly, R Melkote, R Lane, P Lim, D Vitagliano, ... International Journal of Neuropsychopharmacology 22 (10), 616-630, 2019 | 327 | 2019 |
| Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study D Hough, S Gopal, U Vijapurkar, P Lim, M Morozova, M Eerdekens Schizophrenia research 116 (2-3), 107-117, 2010 | 315 | 2010 |
| Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. HY Meltzer, WV Bobo, IF Nuamah, R Lane, D Hough, M Kramer, ... Journal of Clinical Psychiatry 69 (5), 817-829, 2008 | 242 | 2008 |
| Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia A Randomized Clinical Trial J Berwaerts, Y Liu, S Gopal, I Nuamah, H Xu, A Savitz, D Coppola, ... JAMA Psychiatry, 2015 | 236 | 2015 |
| Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study M Kramer, R Litman, D Hough, R Lane, P Lim, Y Liu, M Eerdekens International Journal of Neuropsychopharmacology 13 (5), 635-647, 2010 | 210 | 2010 |
| Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3 R Ochs-Ross, EJ Daly, Y Zhang, R Lane, P Lim, RL Morrison, D Hough, ... The American Journal of Geriatric Psychiatry 28 (2), 121-141, 2020 | 207 | 2020 |
| Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study S Gopal, DW Hough, H Xu, JM Lull, C Gassmann-Mayer, BM Remmerie, ... International clinical psychopharmacology 25 (5), 247-256, 2010 | 197 | 2010 |
| Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2) * Ewa Wajs, MD, PhDa, MS Leah Aluisio, MBA Richard Holder, ... THE JOURNAL OF CLINICAL PSYCHIATRY 81 (3), 2020 | 195 | 2020 |
| Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: A randomized, multicenter, double-blind, noninferiority study AJ Savitz, H Xu, S Gopal, I Nuamah, P Ravenstijn, A Janik, A Schotte, ... Int J Neuropsychophamacol., 2016 | 195 | 2016 |
| A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia G Pandina, R Lane, S Gopal, C Gassmann-Mayer, D Hough, B Remmerie, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 35 (1), 218-226, 2011 | 195 | 2011 |
| Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study … DJ Fu, DF Ionescu, X Li, R Lane, P Lim, G Sanacora, D Hough, H Manji, ... The Journal of clinical psychiatry 81 (3), 6605, 2020 | 189 | 2020 |
| A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia HA Nasrallah, S Gopal, C Gassmann-Mayer, JA Quiroz, P Lim, ... Neuropsychopharmacology 35 (10), 2072-2082, 2010 | 181 | 2010 |
| Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3 … DF Ionescu, DJ Fu, X Qiu, R Lane, P Lim, S Kasper, D Hough, ... International Journal of Neuropsychopharmacology 24 (1), 22-31, 2021 | 165 | 2021 |
| Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia D Hough, JP Lindenmayer, S Gopal, R Melkote, P Lim, V Herben, E Yuen, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 33 (6), 1022-1031, 2009 | 153 | 2009 |
| Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study JM Kent, S Kushner, X Ning, K Karcher, S Ness, M Aman, J Singh, ... Journal of autism and developmental disorders 43, 1773-1783, 2013 | 141 | 2013 |
| A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia S Gopal, U Vijapurkar, P Lim, M Morozova, M Eerdekens, D Hough Journal of Psychopharmacology 25 (5), 685-697, 2011 | 136 | 2011 |
| A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia WW Fleischhacker, S Gopal, R Lane, C Gassmann-Mayer, P Lim, ... International Journal of Neuropsychopharmacology 15 (1), 107-118, 2012 | 127 | 2012 |
Srihari GopalRegeneronVerified email at regeneron.com
